Nasdaq warns Mainz Biomed (MYNZ) over sub-$1.00 bid and possible delisting risk

Rhea-AI Filing Summary

Mainz Biomed N.V. reported that Nasdaq has notified the company its ordinary shares no longer meet the minimum $1.00 bid price requirement, after trading below that level for 30 consecutive business days from February 5 to March 19, 2026. The company has 180 calendar days, until September 16, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. If it does not regain compliance by then, it may qualify for an additional 180‑day period if it meets other initial listing standards and formally indicates an intention to cure, potentially via a reverse stock split. The notice has no immediate effect on the current Nasdaq listing, but failure to cure the deficiency could ultimately lead to delisting, which the company would have the right to appeal.

Positive

• None.

Negative

• Nasdaq minimum bid-price deficiency and delisting risk: The company’s shares traded below $1.00 for 30 consecutive business days, triggering a Nasdaq non-compliance notice and starting a limited window to regain compliance or face potential delisting.

Insights

Equity markets and listing standards analyst

Nasdaq bid-price deficiency introduces delisting risk if compliance is not restored.

Mainz Biomed has fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a formal non-compliance notice. The company now faces a defined window, through September 16, 2026, to lift and sustain its share price.

The rules require the stock to close at or above $1.00 for at least ten consecutive business days. If it meets all other initial listing standards and notifies Nasdaq of its cure plan, it may receive another 180 days, potentially using a reverse stock split to raise the bid price mechanically.

If the company cannot satisfy these conditions, Nasdaq may move to delist the shares, though an appeal process is available. Actual outcomes depend on future trading performance and any corporate actions the company undertakes during the compliance periods.

false 0001874252 P7 00-0000000 0001874252 2026-03-20 2026-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 20, 2026

Mainz Biomed N.V.

(Exact Name of Registrant as Specified in its Charter)

The Netherlands		001-41010		N/A
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Robert Koch Strasse 50, 55129 Mainz, Germany

(Address of Principal Executive Offices) (Zip Code)

+49 6131 5542860

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange On Which Registered
Ordinary Shares, nominal value €0.01 per share		QUCY		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 20, 2026, Mainz Biomed N.V. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s ordinary shares, nominal value €0.01 per share (the “Ordinary Shares”) for the 30 consecutive business days between February 5, 2026, to March 19, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until September 16, 2026 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s Ordinary Shares must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the Compliance Period. In the event the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If the Company meets these requirements, the Company may be granted an additional 180 calendar days to regain compliance. However, if it appears to Nasdaq that the Company will be unable to cure the deficiency, or if the Company is not otherwise eligible for the additional cure period, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting. There can be no assurance that the Company will be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing subsequent to any delisting notification. In the event of such a notification, the Company may appeal the Nasdaq staff’s determination to delist its securities.

The letter has no immediate impact on the listing of the Company’s Ordinary Shares, which will continue to be listed and traded on Nasdaq, subject to the Company’s compliance with the other listing requirements of Nasdaq.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Mainz Biomed N.V.
	By:	/s/ William Caragol
		Name:	William Caragol
		Title:	Chief Financial Officer

Dated: March 25, 2026

3

FAQ

Why did Mainz Biomed (MYNZ) receive a Nasdaq non-compliance notice?

Mainz Biomed received the notice because its ordinary shares’ closing bid price was below $1.00 for 30 consecutive business days from February 5 to March 19, 2026, violating Nasdaq Listing Rule 5550(a)(2) on minimum bid price requirements.

How long does Mainz Biomed (MYNZ) have to regain Nasdaq bid-price compliance?

Mainz Biomed has 180 calendar days, until September 16, 2026, to regain compliance. Its shares must close at or above $1.00 for at least ten consecutive business days during this period to satisfy Nasdaq’s minimum bid-price rule.

What happens if Mainz Biomed (MYNZ) does not regain compliance by September 16, 2026?

If Mainz Biomed does not regain compliance by September 16, 2026, it may still qualify for an additional 180 days if it meets all other initial listing standards and notifies Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split.

Could Mainz Biomed (MYNZ) be delisted from Nasdaq because of this notice?

The notice does not immediately delist Mainz Biomed, but failure to cure the deficiency could lead Nasdaq to move toward delisting. If Nasdaq issues a delisting determination, the company would have the right to appeal that decision through Nasdaq’s procedures.

Is Mainz Biomed’s (MYNZ) stock still trading on Nasdaq after the deficiency notice?

Yes. The company stated that the Nasdaq notice has no immediate impact on the listing of its ordinary shares. They continue to trade on the Nasdaq Capital Market while the company works within the compliance period to address the bid-price issue.

How might Mainz Biomed (MYNZ) attempt to regain Nasdaq bid-price compliance?

To regain compliance, Mainz Biomed must achieve a closing bid price of at least $1.00 for ten consecutive business days. The filing notes it may indicate an intention to cure during a second compliance period, including by effecting a reverse stock split if necessary.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB